IP Library Granted Patent US 9,739,775
Granted Patent B2
US 9,739,775 · App. 14/557,097 · Granted Aug 22, 2017

Methods of using chimeric receptors to identify autoimmune disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,739,775
App. No.
14/557,097
Granted
Aug 22, 2017
Kind
B2
Abstract

The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays.

Claims (17)

1. A method for detecting thyroid-stimulating antibodies, comprising:

a) combining:

1) a sample suspected of containing thyroid-stimulating auto-antibodies and

2) a recombinant cell line comprising a chimeric thyroid stimulating hormone (TSH) receptor gene and a reporter gene, wherein the chimeric TSH receptor gene encodes a polypeptide by nucleotides 45 to 2234 of SEQ ID NO:3, said polypeptide comprising, in an N-terminal to C-terminal direction, the N-terminal portion of the human thyroid stimulating hormone receptor (hTSHR), a portion of the rat leutinizing hormone (rLH) receptor wherein said rLH portion comprises the amino acid sequence encoded by nucleotides 828-1046 of SEQ ID NO:3, and the C-terminal portion of the hTSHR;

b) incubating the sample and recombinant cell line under conditions such that the reporter gene generates and detectable signal; and

c) detecting the signal generated by the reporter gene.

2. The method of claim 1 , wherein the sample is a serum sample.

3. The method of claim 1 , wherein the reporter gene is selected from the group consisting of a bacterial β-galactosidase gene, a bacterial chloramphenicol acetyltransferase gene, a luciferase gene, and a β-glucuronidase gene.

4. The method of claim 1 , wherein the reporter gene is a firefly luciferase gene.

5. The method of claim 1 , wherein the reporter gene allows detection of cAMP.

6. The method of claim 1 , wherein the reporter gene is operably linked to a glycoprotein hormone alpha subunit promoter.

7. The method of claim 1 , wherein the method further comprising measuring the intensity of the signal, wherein the intensity positively correlates with thyrotropin stimulating hormone receptor auto antibody concentration present in the sample.

8. The method of claim 1 , wherein the detecting comprising using a luminometer.

9. The method of claim 1 , wherein the recombinant cell line is an RD cell line or a CHO cell line.

10. The method of claim 1 , wherein the recombinant cell line is stably transfected with the reporter gene.

11. The method of claim 1 , wherein the recombinant cell line is stably transfected with the chimeric TSH receptor gene.

12. The method of claim 1 , wherein the chimeric TSH receptor gene comprises SEQ ID NO:3.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded May 31, 2022
From: BANK OF AMERICA, N.A.
To: QUIDEL CORPORATION
Reel/Frame 060220/0649 →
SECURITY INTEREST Recorded Oct 6, 2017
From: QUIDEL CORPORATION
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 044141/0686 →
CHANGE OF ADDRESS Recorded Jan 12, 2017
From: DIAGNOSTIC HYBRIDS, INC.
To: DIAGNOSTIC HYBRIDS, INC.
Reel/Frame 041351/0846 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2014
From: BROWN, JAMES L.
To: DIAGNOSTIC HYBRIDS, INC.
Reel/Frame 034607/0612 →